Gene Expression Correlates with Lymphocyte Infiltration in Breast Cancer
By LabMedica International staff writers Posted on 30 Dec 2014 |
Image: A histology slide stained with hematoxylin and eosin (H&E) and the corresponding three-dimensional cancer density map, which facilitate the measurement of spatial proximity to cancer for every single lymphocyte in the image (Photo courtesy of The Institute of Cancer Research).
Lymphocytic infiltration is associated with a favorable prognosis and predicts response to chemotherapy in many cancer types, including the aggressive triple-negative breast cancer (TNBC).
A novel high-tech system has been developed for measuring the body's immune response to cancer as a way of assessing how rapidly the disease is likely to progress. The system combines computerized imaging of tumor samples with statistical analysis, and is the first objective method to measure the interaction between a patient's immune system and their tumor.
Scientist at The Institute of Cancer Research (London, UK) analyzed 181 samples from women with triple-negative breast cancer. On average, three tumor sections were obtained from different locations of each primary tumor and placed onto the same slide. Tumor materials sandwiched between these sections were sectioned, mixed and used for molecular profiling, thereby maximizing the biological relevance of multiple data types being generated.
The team developed a system, which split lymphocytes into three classes depending on their location within the tumor, and calculated how many of each type were present in each sample, and how many cancer cells were present. Immune infiltration was scored for 112 of the 181 samples by the pathologists into three categories: absent, mild and severe: absent if there were no lymphocytes, mild if there was a light scattering of lymphocytes and severe if there was a prominent lymphocytic infiltrate. Gene expression data were profiled using the human linkage-12 genotyping beadchip (HT-12) platform (Illumina; San Diego, CA, USA).
Women with fewer than around eleven intra-tumor lymphocytes per 1,000 cancer cells had an average five-year survival rate of 49%, compared with an average of 80% in triple-negative breast cancer as a whole. They also found a correlation between immune infiltration of tumors and increased levels of a protein called cytotoxic T-lymphocyte-associated protein 4, (CTLA4) or cluster of differentiation 152 (CD152), suggesting it could be a potential treatment target in this breast cancer type.
Yinyin Yuan, PhD, the team leader of the study, said, “Our test combines imaging technology with computerized analysis of large amounts of data from tumor samples, which typically contain more than 100,000 cells. We found the technique could accurately identify high-risk tumors that were evading the body's immune system in this type of breast cancer, and hope it can be adapted and added to doctors' arsenal against a variety of cancers.” The study was published on December 10, 2014, in the Journal of The Royal Society Interface.
Related Links:
The Institute of Cancer Research
Illumina
A novel high-tech system has been developed for measuring the body's immune response to cancer as a way of assessing how rapidly the disease is likely to progress. The system combines computerized imaging of tumor samples with statistical analysis, and is the first objective method to measure the interaction between a patient's immune system and their tumor.
Scientist at The Institute of Cancer Research (London, UK) analyzed 181 samples from women with triple-negative breast cancer. On average, three tumor sections were obtained from different locations of each primary tumor and placed onto the same slide. Tumor materials sandwiched between these sections were sectioned, mixed and used for molecular profiling, thereby maximizing the biological relevance of multiple data types being generated.
The team developed a system, which split lymphocytes into three classes depending on their location within the tumor, and calculated how many of each type were present in each sample, and how many cancer cells were present. Immune infiltration was scored for 112 of the 181 samples by the pathologists into three categories: absent, mild and severe: absent if there were no lymphocytes, mild if there was a light scattering of lymphocytes and severe if there was a prominent lymphocytic infiltrate. Gene expression data were profiled using the human linkage-12 genotyping beadchip (HT-12) platform (Illumina; San Diego, CA, USA).
Women with fewer than around eleven intra-tumor lymphocytes per 1,000 cancer cells had an average five-year survival rate of 49%, compared with an average of 80% in triple-negative breast cancer as a whole. They also found a correlation between immune infiltration of tumors and increased levels of a protein called cytotoxic T-lymphocyte-associated protein 4, (CTLA4) or cluster of differentiation 152 (CD152), suggesting it could be a potential treatment target in this breast cancer type.
Yinyin Yuan, PhD, the team leader of the study, said, “Our test combines imaging technology with computerized analysis of large amounts of data from tumor samples, which typically contain more than 100,000 cells. We found the technique could accurately identify high-risk tumors that were evading the body's immune system in this type of breast cancer, and hope it can be adapted and added to doctors' arsenal against a variety of cancers.” The study was published on December 10, 2014, in the Journal of The Royal Society Interface.
Related Links:
The Institute of Cancer Research
Illumina
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans